基于[68Ga]Ga-DOTA-NOC PET/CT的定量肿瘤负荷在分化良好的神经内分泌肿瘤中的作用:超越预后
本研究纳入204例[68Ga]Ga-DOTA-NOC PET/CT阳性的晚期分化良好神经内分泌肿瘤患者,采用本底阈值和相对固定阈值(30%、40%、50%)计算肿瘤负荷。30%相对固定阈值得出的生长抑素受体表达肿瘤体积(SRETV30)和肝脏SRETV30与总生存(OS)显著相关(C-index分别为0.802和0.806)。在155例ki-67指数≤10%的无功能NET患者中,高SRETV30或高肝脏SRETV30者接受奥曲肽长效释放剂(LAR)治疗的無进展生存(PFS)显著更差。
要点
- SRETV30与肝脏SRETV30均与OS显著相关,C-index分别为0.802和0.806。
- ki-67≤10%的无功能NET患者中,高SRETV30(P=0.016)或高肝脏SRETV30(P=0.014)者奥曲肽LAR治疗的PFS显著更差。
- 按SRETV30或肝脏SRETV30归一化的较高奥曲肽LAR剂量与更长的PFS和OS相关。
核心结论
- 基于[68Ga]Ga-DOTA-NOC PET/CT的定量肿瘤负荷与接受奥曲肽LAR治疗的ki-67指数≤10%的无功能NET患者的OS和PFS相关。
- 计算归一化剂量和肝脏归一化剂量可能有助于选择奥曲肽LAR的起始剂量。
研究设计与样本
- 本研究纳入204例[68Ga]Ga-DOTA-NOC PET/CT阳性且PET/CT前未接受药物治疗的晚期NET患者。
- 肿瘤负荷采用基于本底阈值和相对固定阈值(30%、40%、50%)的方法计算。
- 采用Cox回归分析、Harrell C-index和生存分析评估肿瘤负荷对OS和奥曲肽LAR治疗PFS的预后价值。
- 采用分类与回归树(CART)确定肿瘤负荷的最佳阈值。
主要发现
- 30%相对固定阈值得出的SRETV30和肝脏SRETV30与OS显著相关,C-index分别为0.802(95%CI 0.658-0.946)和0.806(95%CI 0.664-0.948)。
- 肝外肿瘤负荷与OS无显著相关(HR 0.617,95%CI 0.241-1.574,P=0.312)。
- 在155例ki-67指数≤10%的无功能NET患者中,高SRETV30(P=0.016)或高肝脏SRETV30(P=0.014)者接受奥曲肽LAR治疗的PFS显著更差。
- 接受按SRETV30或肝脏SRETV30归一化的较高奥曲肽LAR剂量的患者,奥曲肽LAR治疗的PFS延长且OS延长。
关键数值与推荐
- SRETV30与OS的C-index为0.802(95%CI 0.658-0.946)。
- 肝脏SRETV30与OS的C-index为0.806(95%CI 0.664-0.948)。
- 肝外肿瘤负荷与OS的HR为0.617(95%CI 0.241-1.574,P=0.312)。
- 在ki-67指数≤10%的无功能NET患者中,高SRETV30与PFS相关的P=0.016,高肝脏SRETV30与PFS相关的P=0.014。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to elucidate the role of quantitative tumor burden based on PET/CT of somatostatin receptors in well-differentiated neuroendocrine tumors (NETs). METHODS: This study enrolled patients with [68 Ga]Ga-DOTA-NOC PET/CT-positive advanced NETs who did not receive medical treatment prior to PET/CT. Tumor burden was calculated using methods based on the background threshold and relative fixed threshold values (30%, 40%, and 50%). The prognostic value of the measured tumor burden in reference to overall survival (OS) and progression-free survival (PFS) on treatment with octreotide long-acting repeatable (LAR) was assessed using Cox regression analysis, Harrell's C-index, and survival analysis. A classification and regression tree (CART) was used to determine the optimal threshold for tumor burden. RESULTS: A total of 204 patients were included. Somatostatin receptor-expressing tumor volume (SRETV) and liver SRETV derived from a relative fixed threshold of 30% (SRETV30 and liver SRETV30) were statistically significantly associated with OS (C-index: 0.802 [95% confidence interval (CI), 0.658-0.946] and 0.806 [95% CI, 0.664-0.948], respectively). Extrahepatic tumor burden was not correlated with OS (hazard ratio: 0.617, 95% CI: 0.241-1.574, P = 0.312). Among 155 patients with non-functional NETs with a ki-67 index of ≤ 10%, those with a high SRETV30 (P = 0.016) or high liver SRETV30 (P = 0.014) showed statistically significantly worse PFS on treatment with octreotide LAR. Patients receiving a higher dose of octreotide LAR normalized by SRETV30 or liver SRETV30 (a normalized dose or a liver normalized dose) showed prolonged PFS on treatment with octreotide LAR and a prolonged OS. CONCLUSION: Quantitative tumor burden based on [68 Ga]Ga-DOTA-NOC PET/CT was correlated with OS and PFS in patients with non-functional NETs with a ki-67 index of ≤ 10% who received octreotide LAR. Calculating normalized and liver normalized doses may help in selecting the starting dose of octreotide LAR.
引用
- Chen L, Jumai N, He Q, et al. The role of quantitative tumor burden based on [68 Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis. Eur J Nucl Med Mol Imaging. 2022. PMID: 36181533. doi:10.1007/s00259-022-05971-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。